Market Cap
$59.8B
MET
METLIFE INC
$94.43 ▲ +0.08%
Prev close $94.35Market cap$59.8B
ConsensusBuy
12-mo target$105.88 (+12.1%)
▲ Bullish
Analyst conviction 7/10
35 New Institutional Positions15 Institutional Exits Traditional Finance
Snapshot
The big-picture read on MET right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (71%)
Inst. Holders
50 funds
Inst. Value
$31.2B
Inst. Activity
35 buys / 15 sells
Insider Activity
$0.00 buy / $1.7M sell
Insider Net $
-$1.7M
SEC Reports
8
Price chart 30d -2.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Short Volume: MET — 60.7% short (0.6M / 1.0M)
Short: 578,691 | Exempt: 21,846 | TRF Vol: 953,840 | Short Ratio: 60.7% | Off-exchange volume (dark
Sep 8, 2026 Insider
Kennard William E was granted 294 shares
Director @ $95.50 ($28.1K)
Sep 8, 2026 Insider
HUBBARD ROBERT GLENN was granted 618 shares
Director @ $95.50 ($59.0K)
Sep 8, 2026 Insider
Aug 25, 2026 SEC Glaser Daniel S was granted 10 shares
Director @ $95.50 ($955.00)
Metropolitan Life Insurance Co/NY, an affiliate of MetLife Inc, filed a Form 144 notice to sell 104 shares of MetLife co
144 — Impact 1/10
Jun 30, 2026 Inst.
NORGES BANK — NEW
6,819,657 shares ($577.0M)
Jun 30, 2026 Inst.
Jun 29, 2026 SEC ARROWSTREET CAPITAL, LIMITED PARTNERSHIP — ADD
5,808,715 shares ($491.5M)
MetLife disclosed preliminary variable investment income (VII) for Q2 2026 of approximately $220M-$270M pre-tax, which a
8-K — Impact 5/10
Analyst ratings buy % -6.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
71% rate it Buy or better · 24 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | Piper Sandler | UPGRADE | Overweight | 54% |
| Aug 24, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 19, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 11, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 11, 2026 | Keefe, Bruyette & Woods | MAINTAIN | Outperform | 58% |
| Aug 6, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 22, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Jul 21, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Jul 13, 2026 | Evercore ISI Group | MAINTAIN | In-Line | 59% |
| Jul 13, 2026 | Keefe, Bruyette & Woods | MAINTAIN | Outperform | 58% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 12 | 7 | 0 | 0 | 71% | |
| Aug 1, 2026 | 5 | 12 | 7 | 0 | 0 | 71% | |
| Jul 1, 2026 | 5 | 11 | 7 | 0 | 0 | 70% | |
| Jun 1, 2026 | 5 | 11 | 7 | 0 | 0 | 70% | |
| May 1, 2026 | 5 | 11 | 6 | 0 | 0 | 73% | |
| Apr 1, 2026 | 5 | 11 | 6 | 0 | 0 | 73% | |
| Mar 1, 2026 | 5 | 10 | 6 | 0 | 0 | 71% | |
| Feb 1, 2026 | 5 | 10 | 6 | 0 | 0 | 71% |
Price targets
Where 16 covering analysts think MET trades over the next 12 months.
$105.88 +12.1% upside Buy
Current$94.43 Low$84.00 Median$108.00 High$119.00 16 analysts
$84.00$119.00
Analyst rating Buy· 1.9/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 7 neutral · avg impact 2.6/10.
NEUTRAL1441/10
Metropolitan Life Insurance Co/NY, an affiliate of MetLife Inc, filed a Form 144 notice to sell 104
Aug 25, 2026
BEARISH8-K5/10
MetLife disclosed preliminary variable investment income (VII) for Q2 2026 of approximately $220M-$2
Jun 29, 2026
NEUTRAL1441/10
Metropolitan Life Insurance Co/NY, an affiliate of MetLife Inc, filed a Form 144 to sell 72 shares o
Jun 19, 2026
NEUTRAL1441/10
Metropolitan Life Insurance Co/NY files Form 144 to sell 128 shares of MetLife Inc common stock, wit
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: MET — 60.7% short (0.6M / 1.0M)
Short: 578,691 | Exempt: 21,846 | TRF Vol: 953,840 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: MET — 68.4% short (0.7M / 1.1M)
Short: 748,339 | Exempt: 0 | TRF Vol: 1,094,216 | Short Ratio: 68.4% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: MET — 59.6% short (0.6M / 1.0M)
Short: 591,189 | Exempt: 4,333 | TRF Vol: 992,503 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: MET — 58.4% short (0.7M / 1.1M)
Short: 666,095 | Exempt: 1,724 | TRF Vol: 1,140,862 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: MET — 74.6% short (0.6M / 0.9M)
Short: 638,335 | Exempt: 0 | TRF Vol: 855,468 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.64 | $2.50–$2.95 | 11.5% | +3.6% | 7↑ 2↓ | $20.0B | 15 |
| Next Q | $2.61 | $2.45–$2.87 | 4.8% | +0.3% | 7↑ 2↓ | $20.6B | 14 |
| Current FY | $9.91 | $7.19–$10.47 | 12.3% | +0.7% | 14↑ 0↓ | $79.8B | 18 |
| Next FY | $11.12 | $10.76–$11.63 | 12.2% | -0.1% | 13↑ 1↓ | $83.6B | 16 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.642 | — |
| 7d ago | $2.564 | +0.078 |
| 30d ago | $2.550 | +0.092 |
| 60d ago | $2.528 | +0.114 |
| 90d ago | $2.541 | +0.101 |
Institutional ownership
Which big funds own MET (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $31.2B total value (368,408,528 shares) as of 2026-Q2. Top holders: BlackRock,, DODGE, VANGUARD. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 51,786,925 | $4.4B | 14.0% | — |
| DODGE & COX | 48,431,150 | $4.1B | 13.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 35,483,789 | $3.0B | 9.6% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 30,031,431 | $2.5B | 8.1% | — |
| STATE STREET CORP | 25,336,999 | $2.1B | 6.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 13,309,884 | $1.1B | 3.6% | — |
| MORGAN STANLEY | 12,532,097 | $1.1B | 3.4% | — |
| PZENA INVESTMENT MANAGEMENT LLC | 11,130,983 | $941.8M | 3.0% | — |
| DIMENSIONAL FUND ADVISORS LP | 7,190,673 | $608.5M | 2.0% | — |
| Invesco Ltd. | 6,929,794 | $586.3M | 1.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 6,819,657 | — | $577.0M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 3,098,649 | 5,808,715 | +87.5% | $491.5M |
| Amundi | ADD | 2,559,946 | 3,627,717 | +41.7% | $306.9M |
| AMERIPRISE FINANCIAL INC | TRIM | 6,759,903 | 3,474,206 | -48.6% | $294.0M |
| HSBC HOLDINGS PLC | ADD | 1,992,623 | 2,568,764 | +28.9% | $217.2M |
| UBS Group AG | TRIM | 3,605,168 | 2,440,347 | -32.3% | $206.5M |
| AMERICAN CENTURY COMPANIES INC | ADD | 1,682,680 | 2,162,758 | +28.5% | $183.0M |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 518,065 | 1,270,174 | +145.2% | $107.5M |
| Man Group plc | TRIM | 2,080,887 | 1,223,668 | -41.2% | $103.5M |
| Freestone Grove Partners LP | NEW | — | 1,183,835 | — | $100.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$1.7M — $0.00 bought, $1.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Kennard William E | Director | AWARD | 294 | $95.50 | $28.1K |
| Sep 8, 2026 | HUBBARD ROBERT GLENN | Director | AWARD | 618 | $95.50 | $59.0K |
| Sep 8, 2026 | Glaser Daniel S | Director | AWARD | 10 | $95.50 | $955.00 |
| Sep 8, 2026 | Harris Carla A | Director | AWARD | 42 | $95.50 | $4.0K |
| Sep 8, 2026 | Johnson Jeh C. | Director | AWARD | 59 | $95.50 | $5.6K |
| Sep 8, 2026 | TADROS RAMY | President, U.S. Business | AWARD | 115 | $95.50 | $11.0K |
| Sep 8, 2026 | MCKENZIE DIANA | Director | AWARD | 157 | $95.50 | $15.0K |
| Sep 8, 2026 | Hay Laura J | Director | AWARD | 39 | $95.50 | $3.7K |
| Sep 8, 2026 | Mumenthaler Christian Stephane | Director | AWARD | 21 | $95.50 | $2.0K |
| Aug 31, 2026 | PAPPAS BILL | EVP, Global Tech. & Ops. | TAX W/H | 4,030 | $95.17 | $383.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MET.
Shares short
12,285,410
Settlement Sep 15, 2026
Change vs prior
+3.6%
Semi-monthly cycle
Days to cover
4.4
At avg daily volume
Of shares outstanding
≈1.9%
Estimate — not % of float
All MET filing & press-release reports (8)
- 144 reportAug 25, 2026
- 8-K reportJun 29, 2026
- 144 reportJun 19, 2026
- 144 reportMay 28, 2026
- 8-K reportMay 15, 2026
- 8-K reportApr 7, 2026
- 8-K reportMar 5, 2026
- 8-K reportFeb 24, 2026